Literature DB >> 22634354

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Ben Warner, Adam W Harris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22634354     DOI： 10.1053/j.gastro.2012.03.055

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  4 in total

Review 1.  "Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion.

Authors:  Cristiano Pagnini; Francesca Menasci; Stefano Festa; Gianenrico Rizzatti; Gianfranco Delle Fave
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

2.  Trends in Worldwide Research in Inflammatory Bowel Disease Over the Period 2012-2021: A Bibliometric Study.

Authors:  Kemin Li; Chenzhe Feng; Haolin Chen; Yeqian Feng; Jingnan Li
Journal:  Front Med (Lausanne)       Date:  2022-05-19

3.  Dose Escalation and Healthcare Resource Use among Ulcerative Colitis Patients Treated with Adalimumab in English Hospitals: An Analysis of Real-World Data.

Authors:  Christopher M Black; Eric Yu; Eilish McCann; Sumesh Kachroo
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

4.  Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?

Authors:  Jihye Park; Jae Hee Cheon
Journal:  Intest Res       Date:  2017-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.